Previous investigations of the Leishmania infantum eIF4A-like protein (LieIF4A) as a potential drug target delivered cholestanol derivatives inhibitors. Here, we investigated the mode of action of cholesterol derivatives as a novel scaffold structure of LieIF4A inhibitors on the RNA-dependent ATPase activity of LieIF4A and its mammalian ortholog (eIF4AI). We compared their biochemical effects on RNA-dependent ATPase activities of both proteins and investigated if rocaglamide, a known inhibitor of eIF4A, could affect LieIF4A as well. Kinetic measurements were conducted at different concentrations of ATP, of the compound and in the presence of saturating whole yeast RNA concentrations. Kinetic analyses showed different ATP binding affinities for the two enzymes as well as different sensitivities to 7-α-aminocholesterol and rocaglamide. The 7-α-aminocholesterol inhibited LieIF4A with a higher binding affinity relative to cholestanol analogs. Cholesterol, another tested sterol, had no effect on the ATPase activity of LieIF4A or eIF4AI. The 7-α-aminocholesterol demonstrated an anti-Leishmania activity on L. infantum promastigotes. Additionally, docking simulations explained the importance of the double bond between C5 and C6 in 7-α-aminocholesterol and the amino group in the C7 position. In conclusion, Leishmania and mammalian eIF4A proteins appeared to interact differently with effectors, thus making LieIF4A a potential drug against leishmaniases.
DEAD-box RNA helicases are ubiquitous proteins found in all kingdoms of life and that are associated with all processes involving RNA. Their central roles in biology make these proteins potential targets for therapeutic or prophylactic drugs. The Ded1/DDX3 subfamily of DEAD-box proteins is of particular interest because of their important role(s) in translation. In this paper, we identified and aligned the protein sequences of 28 different DEAD-box proteins from the kinetoplast-protozoan parasite Leishmania infantum, which is the cause of the visceral form of leishmaniasis that is often lethal if left untreated, and compared them with the consensus sequence derived from DEAD-box proteins in general, and from the Ded1/DDX3 subfamily in particular, from a wide variety of other organisms. We identified three potential homologs of the Ded1/DDX3 subfamily and the equivalent proteins from the related protozoan parasite Trypanosoma brucei, which is the causative agent of sleeping sickness. We subsequently tested these proteins for their ability to complement a yeast strain deleted for the essential DED1 gene. We found that the DEAD-box proteins from Trypanosomatids are highly divergent from other eukaryotes, and consequently they are suitable targets for protein-specific drugs.
The DEAD‐box proteins of the superfamily II (SF2) RNA/DNA helicases are typically found to be ATP‐dependent RNA binding proteins and RNA‐dependent ATPases; however, they have poor, nonprocessive, RNA unwinding activity. Moreover, cells contain multiple variants that are associated with specific cellular processes, and they are generally not interchangeable. Thus, they can be thought of as ATP‐dependent switches to control the progression and directionality of cellular metabolism and catabolism. We have characterized a DEAD‐box protein (LINF08) from the trypanosomatid parasite Leishmania infantum that has homology to the spliceosome protein DDX46/Prp5. It is expressed in the nucleus of the flagellated promastigotes and the immobile axenic amastigotes. It has very high intrinsic ATPase activity that is independent of added nucleic acids, and it is activated both by the usual bound magnesium cation and by calcium, which is a cation that typically does not directly participate in catalysis. DDX46/Prp5 in other eukaryotes is involved in the early proofreading steps of spliceosome assembly to resolve structural aberrations between the U2 small nuclear RNA (snRNA) and the splice junction. Although trypanosomes typically lack introns, all of the mRNAs are transcribed as polycistronic RNAs that are processed into individual mRNAs involving a process known as SL‐dependent trans splicing. Trypanosomes retain the spliceosome machinery but the snRNAs are in an abbreviated form. Thus, although LINF08 appears to be a DDX46/Prp5 homolog, it has probably evolved for the unusual splicing machinery and highly variable environment of the parasite.
13 March 2026 in Frontiers in Cellular and Infection Microbiology
Introduction: Drug repurposing is a promising strategy for identifying new treatments against neglected tropical diseases such as leishmaniases, which are endemic in Asia, Africa, the Americas, and Southern Europe, offering the advantages of reduced development time and cost. In this context, computational and biochemical investigation of therapeutic targets plays a key role in guiding the selection of effective drug candidates. Methods: In this study, we investigated Leishmania infantum 5′-methylthioadenosine phosphorylase (LiMTAP) as a potential drug target by evaluating criteria defining such targets, including assayability, biochemical properties, and structural features enabling inhibitor selection. Trimeric 3D models of Li MTAP were generated, followed by virtual screening and docking of FDA-approved drugs. A robust miniaturized robotic assay was developed for recombinant Li MTAP to enable biochemical validation. Seven predicted drug candidates were subsequently tested in enzymatic and biological assays. Results: Two compounds—Labetalol and Halofuginone—inhibited Li MTAP activity with IC₅₀ values ranging from 200–400 µg/mL. The antileishmanial activity of all seven compounds was evaluated on extracellular promastigotes; four compounds (Dobutamine, Halofuginone, Labetalol, and Pentamidine) showed activity. Pentamidine and Dobutamine did not inhibit Li MTAP despite their anti-promastigote effects. Labetalol exhibited an IC 50 of 29.67 µg/mL against extracellular promastigotes and showed no significant toxicity on THP-1 macrophages at effective doses (CC 50 = 98.29 µg/mL). When tested on intracellular amastigotes, Labetalol demonstrated an IC 50 value of 19.10 µg/mL. Discussion: This study confirms the in silico predictions through in vitro validation and highlights repurposed drugs as promising anti- Leishmania candidates .